With a second wave of Humira (adalimumab) rivals set to hit the US in just a few months time, Sandoz has gained US Food and Drug Administration approval for a citrate-free, high-concentration 100mg/ml version of its already approved Hyrimoz (adalimumab-adaz) biosimilar.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?